Can this platform discover antibodies against toxic or non-immunogenic antigens?

Yes. In vitro display technologies, including the combined phage-yeast platform, do not require animal immunization and are well-suited for targets that are toxic, non-immunogenic, or otherwise unsuitable for conventional hybridoma approaches.

How is affinity maturation handled in this combined platform?

Affinity maturation is integrated into the workflow through iterative rounds of library diversification (e.g., error-prone PCR or targeted CDR randomization) followed by FACS-based sorting to select variants with improved binding characteristics.

What is the typical success rate for obtaining unique clones against challenging targets?

Success rates are target-dependent, but the combined platform strategy - leveraging phage display diversity and yeast display precision - substantially increases the probability of isolating high-affinity, specific binders, including against complex membrane proteins and challenging epitopes.

What provisions cover material handover and data confidentiality?

Standard material transfer agreements and confidentiality provisions are established at project initiation. Specific terms can be discussed with our team to accommodate client requirements.

Human Monoclonal Antibody Discovery Service by Combined Phage & Yeast Display

Services Workflow Platform Advantages Related Services FAQ

Integrated Phage & Yeast Display for Human mAb Identification

Fig.1 Precise Operation (Creative Biolabs AI)

Conventional hybridoma-based antibody generation is constrained by immunogenicity limitations, prolonged timelines, and the necessity for subsequent humanization. Single-platform display approaches (phage or yeast alone) each present inherent trade-offs between library diversity and screening precision. Creative Biolabs offers a human monoclonal antibody discovery service that integrates phage display library enrichment with yeast display-based fluorescence-activated cell sorting (FACS) screening.

This combined strategy leverages the vast initial diversity of phage libraries while capitalizing on the eukaryotic expression, proper protein folding, post-translational modifications, and quantitative FACS-based affinity ranking afforded by yeast display. The platform is applicable to labeled target antigens and enables the rapid identification of high-affinity, high-specificity human monoclonal antibodies, including against poorly immunogenic or complex targets.

Consult technical specialists for full technical details →

Related Services

Fig.2 Grid (Creative Biolabs AI)

Yeast Display Library Construction Services

Custom yeast display library development by Creative Biolabs delivers high-quality templates for downstream screening workflows.

Fig.3 Planet (Creative Biolabs AI)

Yeast Display Library Screening Services

Precise biopanning procedures quickly enrich clones capable of specific binding to target molecules.

Fig.4 Microscope (Creative Biolabs AI)

Yeast Display based Antibody Discovery Services

High-throughput yeast display screening retrieves antibody candidates with outstanding specificity and binding affinity.

Fig.5 Molecule (Creative Biolabs AI)

Yeast Display based Protein Optimization & Engineering Services

Targeted protein modification and engineering enhance molecular binding affinity and structural stability.

Fig.6 Research (Creative Biolabs AI)

Yeast Display based Peptide Discovery Services

High-throughput screening identifies target-interacting peptides applicable to peptide therapeutics and molecular probes.

For detailed specifications and project discussion, a quote request is welcomed. Request a Quote

Transparent Flow, Total Control, Trustworthy Output

The entire workflow is implemented in clear, sequential steps to guarantee full clone traceability and stage-wise quality control.

Starting materials:

Purified target protein antigen or comprehensive protein data (sequence, structure and biological background).

Key steps:

Phase 1: Ultra-Large Diversity Library Construction & Screening (Phage Display)

Construct antibody libraries via our phage display system or our ready-to-use premade libraries to capture maximum genetic diversity (up to 10¹¹). This stage utilizes high-throughput preliminary panning to rapidly eliminate non-binders and bridge the gap by harnessing the sheer speed of phage selection.
Phase 2: Precision High-Throughput Sorting & Maturation (Yeast Display)

Seamlessly transfer the enriched antibody pool into our yeast display platform in various formats (scFv, Fab, VHH, or full-length IgG). Benefiting from the eukaryotic quality of yeast, this stage ensures correct protein folding and mammalian-like PTMs. Multi-parameter FACS is then deployed for quantitative affinity, specificity, and functional screening to achieve precise affinity maturation.

Deliverables:

Deliverables include purified antibodies, variable region gene sequences, assay reports, recombinant plasmids and more. For detailed information, please consult our technical specialists.

Complete traceability covering raw material receipt through finished product delivery, Discover More →

Our Platform

Creative Biolabs integrates phage and yeast dual-display technology to overcome inherent limitations of single display platforms. Phage display generates ultra-diverse libraries, while yeast display enables precise screening for target antibodies with ideal functional activity.

For in-depth technical information, visit our dedicated pages: Yeast Display Platform and Phage Display Platform.

To evaluate platform compatibility with your research project, Request a Quote Now.

Why Choose Creative Biolabs?

Differentiators backed by experience

Primary application directions

Fig.11 Reagent (Creative Biolabs AI)

More controlled and quantitative screening

Compensate inherent limitations of single display platforms and efficiently obtain target antibodies with optimal functional activity via FACS.

Fig.12 Innovation (Creative Biolabs AI)

Efficient enrichment of specific clones

Multiple sorting rounds with adjustable stringency yield high-confidence hits even from challenging libraries.

Fig.13 Compliance (Creative Biolabs AI)

Dedicated scientific staff

Direct, real-time communication with project leaders ensures alignment on selection strategies and iterative optimization.

Fig.14 Audit (Creative Biolabs AI)

Proven track record in antibody discovery

The team has successfully delivered human monoclonal antibodies across therapeutic areas.

Contact Our Technical Specialists to discuss your target.

Related Service – Broader Binder Discovery

Yeast Display based Binder Discovery Services

Covers antibody, TCR, peptide, and protein binder identification from discovery to lead optimization.

Contact technical consultants for tailored experimental protocols!

Quick Answers

Can this platform discover antibodies against toxic or non-immunogenic antigens?
Yes. In vitro display technologies, including the combined phage-yeast platform, do not require animal immunization and are well-suited for targets that are toxic, non-immunogenic, or otherwise unsuitable for conventional hybridoma approaches.
How is affinity maturation handled in this combined platform?
Affinity maturation is integrated into the workflow through iterative rounds of library diversification (e.g., error-prone PCR or targeted CDR randomization) followed by FACS-based sorting to select variants with improved binding characteristics.
What is the typical success rate for obtaining unique clones against challenging targets?
Success rates are target-dependent, but the combined platform strategy - leveraging phage display diversity and yeast display precision - substantially increases the probability of isolating high-affinity, specific binders, including against complex membrane proteins and challenging epitopes.
What provisions cover material handover and data confidentiality?
Standard material transfer agreements and confidentiality provisions are established at project initiation. Specific terms can be discussed with our team to accommodate client requirements.

For additional questions or to discuss specific project requirements, please contact our scientific team.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: